FIELD D 

 Columns 12, 13, 14, 

 15, 16, and 17 



compound, but the CBCC has not made this provision. Therefore, this action of the secondary 

 compound must always be included in the written abstract portion for Field T-2 and whenever a 

 secondary compound's action is synergized, antagonized, or simulated by or is additive with the 

 test compound, the written abstract on the code sheet must be consulted to understand the action of 

 the secondary compound which has been affected, as indicated in Field T-l, by the test compound. 



10. Procedures when conflicts occur in the use of Field D 



Ideally, a special coding field would be established for each of the four uses for a secondary 

 compound listed in the General Use section. Then, if a test technique involved two of those aspects 

 (e. g. , antagonism evaluated by comparison to a standard), each could be indicated in its respective 

 position on the Code Sheet and IBM punched card. The great infrequency of tests in which this 

 occurs, however, makes impractical reserving so many IBM columns (12 columns for two of the uses 

 or 24 columns for all four uses of secondary compounds). For this reason, only the single field of 6 

 columns has been reserved for any one of four possible uses. As a result, when occasionally test 

 data involve two secondary compounds used in two of the four possible ways, having only one field, 

 Field D, for all the uses of secondary compound poses a problem of competition for the field. The 

 competition occurs with at least four general situations. These are described below as Conflicts A, 

 B, C, and D, with an explanation of CBCC procedure for each case. 



A. When there is an antagonized, synergized, or simulated compound or a compound 

 whose action is additive with the test compound (i. e. , a Field D entry called for 

 by Field T-l, Symbols 8, 9, A, or C) and the metabolism section of Field T-2 

 (Symbols F6--, F8--, F9--, etc. ) calls for the entry of a compound in Field D. 



In this case, the compound antagonized, synergized, or simulated or the 

 compound whose action is additive with that of the test compound ( Field T- 1 ) 

 is coded in Field D . 



The compound called for by Field T-2 is merely written on the Code Sheet, 

 in the written abstract portion of Field T-2 ; the general class to which the 

 compound belongs (i.e., --1 to --G under Symbols F6- -, F8--, etc., and 



1 to L under Symbols FF1- to FFD-) is coded in Field T-2 in the usual 



way. That compound written in Field T-2 is not coded in Field D nor anywhere 

 else. The code line will then state that the test compound antagonizes (or 

 synergizes or simulates) the secondary compound's effect on the metabolism 

 as coded in Field T-2. Note that the written description in Field T-2 must 

 include the secondary compound's action, since there is no way to code this 

 (inasmuch as Field T-l is occupied with the action of the test compound, as 

 explained above in Division 9). 



B. When there is an antagonized or synergized compound or a compound whose action 

 is additive with the test compound or which the test compound simulates (i. e. , a 

 compound in Field D called for by-Field T- 1 Symbols 8, 9, A, or C) and the 

 evaluation of the action is made by comparison with a standard (Field X, Symbols 

 03 or 04) which must also be in Field D. 



Two lines must be coded, if the action is positive. 



The first line is coded with the symbol for "antagonizes" (or "synergizes") 

 in Field T- 1 and with the antagonized (or synergized) compound in Field D ; 

 the criterion of evaluation for this line must be "Author's Evaluation", 

 Field X, Symbol 01. 



The second line is also coded with the symbol for "antagonizes" (or 

 "synergizes") in Field T-l and the standard compound , to which the test 

 compound is compared for evaluation, is coded in Field D (including an 

 asterisk in Column 17); the criterion for evaluation is either 03 or 04 of 

 Field X. If the action is negative, this second line is not required. 



- 15 



